Cholangiocarcinoma laboratory findings

	Cholangiocarcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cholangiocarcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cholangiocarcinoma laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cholangiocarcinoma laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cholangiocarcinoma laboratory findings
CDC on Cholangiocarcinoma laboratory findings
Cholangiocarcinoma laboratory findings in the news
Blogs on Cholangiocarcinoma laboratory findings
Directions to Hospitals Treating Cholangiocarcinoma
Risk calculators and risk factors for Cholangiocarcinoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2] [3] [4], Suveenkrishna Pothuru, M.B,B.S. [5]

Overview[edit | edit source]

Laboratory tests for cholangiocarcinoma include aspartate aminotransferase (AST) and alanine aminotransferase (ALT), prothrombin time, albumin and total protein, bilirubin, L-Lactate dehydrogenase and alkaline phosphatase.

Laboratory Findings[edit | edit source]

Laboratory findings consistent with the diagnosis of cholangiocarcinoma include:

Liver function tests[edit | edit source]

Patients with cholangiocarcinoma have elevated concentration of following tests, which is usually suggestive of cholestatic pattern:^[1]^[2]
Prothrombin time
Albumin and total protein
Bilirubin
L-Lactate dehydrogenase
Alkaline phosphatase
Gamma glutamyl transferase
Alpha-fetoprotein
Transaminase levels (aspartate aminotransferase (AST), and alanine aminotransferase (ALT)) may initially be normal among patients with cholangiocarcinoma.

Carcinoembryonic antigen[edit | edit source]

Serum levels of carcinoembryonic antigen (CEA) are often elevated, but not sensitive or specific enough to be used as a screening test.
It may be useful in association with imaging findings for suspected diagnosis of cholangiocarcinoma.^[3]^[4]

Carbohydrate antigen 19-9 (CA 19-9)[edit | edit source]

CA 19-9 is a protein released by cancers of the pancreas and bile ducts.^[5]
An elevated concentration of CA 19-9 is suggestive of pancreatic cancer and cholangiocarcinoma.
CA 19-9 levels are not specific enough to be used as a screening test.^[6]
It can be used as a tumor marker to determine response to chemotherapy.

References[edit | edit source]

↑ Van Beers BE (2008). "Diagnosis of cholangiocarcinoma". HPB (Oxford). 10 (2): 87–93. doi:10.1080/13651820801992716. PMC 2504383. PMID 18773062.
↑ Patel T (2011). "Cholangiocarcinoma--controversies and challenges". Nat Rev Gastroenterol Hepatol. 8 (4): 189–200. doi:10.1038/nrgastro.2011.20. PMC 3888819. PMID 21460876.
↑
Studies of the performance of serum markers for cholangiocarcinoma (such as carcinoembryonic antigen and CA19-9) in patients with and without primary sclerosing cholangitis include the following:
- Nehls O, Gregor M, Klump B (2004). "Serum and bile markers for cholangiocarcinoma". Semin Liver Dis. 24 (2): 139–54. PMID 15192787.
- Siqueira E, Schoen R, Silverman W, Martin J, Rabinovitz M, Weissfeld J, Abu-Elmaagd K, Madariaga J, Slivka A, Martini J (2002). "Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis". Gastrointest Endosc. 56 (1): 40–7. PMID 12085033.
- Levy C, Lymp J, Angulo P, Gores G, Larusso N, Lindor K (2005). "The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis". Dig Dis Sci. 50 (9): 1734–40. PMID 16133981.
- Patel A, Harnois D, Klee G, LaRusso N, Gores G (2000). "The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis". Am J Gastroenterol. 95 (1): 204–7. PMID 10638584.
↑ Chen CY, Shiesh SC, Tsao HC, Lin XZ (2002). "The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis". Hepatogastroenterology. 49 (45): 616–20. PMID 12063953.
↑ Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, Suh KS, Lee KU, Park YH (2005). "Actual long-term outcome of extrahepatic bile duct cancer after surgical resection". Ann. Surg. 241 (1): 77–84. PMC 1356849. PMID 15621994.
↑ Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR (2004). "Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA". World J. Gastroenterol. 10 (3): 427–32. PMC 4724921. PMID 14760772.

Template:WH Template:WS

[pmid18773062-1] Van Beers BE (2008). "Diagnosis of cholangiocarcinoma". HPB (Oxford). 10 (2): 87–93. doi:10.1080/13651820801992716. PMC 2504383. PMID 18773062.

[pmid21460876-2] Patel T (2011). "Cholangiocarcinoma--controversies and challenges". Nat Rev Gastroenterol Hepatol. 8 (4): 189–200. doi:10.1038/nrgastro.2011.20. PMC 3888819. PMID 21460876.

[3] Studies of the performance of serum markers for cholangiocarcinoma (such as carcinoembryonic antigen and CA19-9) in patients with and without primary sclerosing cholangitis include the following:
Nehls O, Gregor M, Klump B (2004). "Serum and bile markers for cholangiocarcinoma". Semin Liver Dis. 24 (2): 139–54. PMID 15192787.

Siqueira E, Schoen R, Silverman W, Martin J, Rabinovitz M, Weissfeld J, Abu-Elmaagd K, Madariaga J, Slivka A, Martini J (2002). "Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis". Gastrointest Endosc. 56 (1): 40–7. PMID 12085033.

Levy C, Lymp J, Angulo P, Gores G, Larusso N, Lindor K (2005). "The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis". Dig Dis Sci. 50 (9): 1734–40. PMID 16133981.

Patel A, Harnois D, Klee G, LaRusso N, Gores G (2000). "The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis". Am J Gastroenterol. 95 (1): 204–7. PMID 10638584.

[4] Nehls O, Gregor M, Klump B (2004). "Serum and bile markers for cholangiocarcinoma". Semin Liver Dis. 24 (2): 139–54. PMID 15192787.

[5] Siqueira E, Schoen R, Silverman W, Martin J, Rabinovitz M, Weissfeld J, Abu-Elmaagd K, Madariaga J, Slivka A, Martini J (2002). "Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis". Gastrointest Endosc. 56 (1): 40–7. PMID 12085033.

[6] Levy C, Lymp J, Angulo P, Gores G, Larusso N, Lindor K (2005). "The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis". Dig Dis Sci. 50 (9): 1734–40. PMID 16133981.

[7] Patel A, Harnois D, Klee G, LaRusso N, Gores G (2000). "The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis". Am J Gastroenterol. 95 (1): 204–7. PMID 10638584.

[pmid12063953-4] Chen CY, Shiesh SC, Tsao HC, Lin XZ (2002). "The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis". Hepatogastroenterology. 49 (45): 616–20. PMID 12063953.

[pmid15621994-5] Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, Suh KS, Lee KU, Park YH (2005). "Actual long-term outcome of extrahepatic bile duct cancer after surgical resection". Ann. Surg. 241 (1): 77–84. PMC 1356849. PMID 15621994.

[pmid14760772-6] Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR (2004). "Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA". World J. Gastroenterol. 10 (3): 427–32. PMC 4724921. PMID 14760772.

[1]

[2]

[3]

[4]

[5]

[6]